Strategic Partnership Focuses on Target Drug Delivery

Calvert Research and Auburn University announced a joint research project entitled Targeted Drug Delivery.  Undertaken through the Auburn University Department of Pathobiology, the six-month study is under the direction of Dr. Valery Petrenko. Dr. Lonnie Bookbinder, West Coast Regional Director, is coordinating the research on behalf of Calvert Research.

The study will center on the hypothesis that targeting siRNA-containing pharmaceutical nanocarriers, such as liposomes, with breast tumor-specific phage proteins may significantly enhance their anti-cancer activity. “This particular study was selected after an extensive nationwide effort to research numerous potential delivery technologies,” stated Dr. Booklbinder.  He continued by adding: “Calvert Research looks forward to advancing science through this partnership with Auburn University and Dr. Petrenko.”

“The Auburn project fits our plans to invest in novel  therapeutic approaches that will advance clinical development of new  drug compounds. We share the belief that future pharmaceuticals and biologicals will have targeted delivery,” explained Russ McLauchlan, CEO of Calvert Holdings, Inc.  “Our alliance with Auburn University gives us a position in this growing field.”

Scheduled to conclude in April 2009, the study’s results will be published by Auburn University.

CureDM, Inc., a biopharmaceutical company developing new therapies to prevent, ameliorate, or reverse both type 1 and 2 diabetes, announces successful stabilization of their patented Human proIslet Peptide (HIP). By stabilizing HIP, CureDM improved its bioavailability. Recently completed studies indicate that human dosage requirements may be as much as 100-fold lower than the native form. HIP is a 14-amino acid human peptide derived from a specific human gene responsible for populating the pancreas with islets, which contain the cells that secrete insulin and other hormones necessary to prevent diabetes.

According to the CEO of CureDM, Loraine V. Upham,

“Meeting this milestone has a significant impact on the commercial value of Human proIslet Peptide. Not only does this mean lower costs associated with the manufacture and commercialization, but also potentially better safety and tolerable outcomes in human trials.”

CureDM has filed with the FDA and anticipates approval for commencement of human studies in early 2009.

Further studies are underway to determine just how low of a dose is possible. Previous studies have confirmed that the stabilization of HIP did not adversely affect the efficacy and demonstrated that normal glucose levels were achieved after 25 days of treatment and remained normal after the therapy was stopped.

About HIP
Human proIslet Peptide (HIP) stimulates the differentiation of pancreatic progenitor cells, which are present in the adult pancreas, into new insulin-producing islets. Each new islet contains pools of beta cells which make insulin. It is hypothesized that treatment with this therapeutic will restore human pancreatic function without the use of stem cells.

About CureDM
The CureDM approach to restore new insulin-producing cells through islet neogenesis can potentially reverse both type 1 and type 2 diabetes. Patients with type 1 diabetes will require pretreatment with an immune tolerance agent to protect new islets formed by HIP. CureDM, Inc., located at the Lankenau Institute for Medical Research on the Lankenau Hospital campus in Wynnewood, PA, is developing peptide therapeutics using a platform that combines bioinformatics, proteomics and Human Genome sequence data. This method has enabled the CureDM scientific team to determine the proteins involved in, and probable mechanisms of islet neogenesis in humans.

For more information about CureDM, visit